Long-lasting neuroadaptations in the glutamatergic corticostriatal circuitry have been suggested to be responsible for the persisting nature of drug addiction. In particular, animal models have linked the metabotropic glutamate receptor 5 (mGluR5) to drug-seeking behavior and extinction learning. Accordingly, blocking mGluR5s attenuated self-administration of cocaine and other addictive drugs in rats. How these animal findings extend to humans remains unclear. Therefore, we investigated if human cocaine users (CU) exhibit altered mGluR5 availability compared with drug-naïve control subjects. Seventeen male controls (11 smokers) and 18 male cocaine users (13 smokers) underwent positron emission tomography with 11 C-ABP688 to quantify mGluR5 availability in 12 volumes of interest in addiction-related brain areas. Drug use was assessed by self-report and quantitative hair toxicology. CU and controls did not significantly differ in regional mGluR5 availability. In contrast, smokers (n ¼ 24) showed significantly lower mGluR5 density throughout the brain (mean 20%) compared with non-smokers (n ¼ 11). In terms of effect sizes, lower mGluR5 availability was most pronounced in the caudate nucleus (d ¼ 1.50, 21%), insula (d ¼ 1.47, 20%), and putamen (d ¼ 1.46, 18%). Duration of smoking abstinence was positively associated with mGluR5 density in all brain regions of interest, indicating that lower mGluR5 availability was particularly pronounced in individuals who had smoked very recently. Specifically tobacco smoking was associated with lower mGluR5 availability in both CU and controls, while cocaine use was not linked to detectable mGluR5 alterations. These findings have important implications regarding the development of novel pharmacotherapies aimed at facilitating smoking cessation.
INTRODUCTION
Cocaine addiction continues to be a major public health concern resulting in high societal and economic costs. 1, 2 Notably, cocaine is the second most used illicit drug with 13-20 million users worldwide. Annual prevalence rates are relatively high with 1.6% in North America, 1.3% in Central Europe, and 1.5-1.9% in Oceania. 3 The harmful effects associated with cocaine use become evident through the high treatment demand related to psychostimulants. Accordingly, 17% of all patients who entered drug treatment programs in the USA 4 and 23% of the drugseeking patients in Europe did so for the treatment of stimulant addiction. 5 Despite the high treatment demand, effective pharmacotherapies for cocaine addiction are currently lacking. 6 Although acutely reinforcing effects of addictive drugs are mainly dependent on the mesocorticolimbic dopamine system, 7 accumulating preclinical research has provided evidence that longer-lasting neuroadaptations in glutamatergic corticolimbic circuitries may be responsible for the persisting nature of cocaine addiction. [8] [9] [10] In particular, glutamatergic projections from the prefrontal cortex (PFC) to the nucleus accumbens (NAcc) appear to be relevant for drug reinstatement and drug-seeking behavior in animals and may also have an important role in craving and relapse-related behaviors in psychostimulant-addicted humans. 9, 11 Chronic self-administration in rats resulted in lower basal extracellular, non-synaptic glutamate levels in the NAcc, which in turn has been associated with downregulation of group I and II metabotropic glutamate receptor (mGluR) expression and function in rats, [12] [13] [14] [15] [16] [17] resulting in altered synaptic plasticity. Impaired plasticity has been suggested to contribute to the relative inability to form adaptive behaviors that help inhibiting relapse in drug users.
How preclinical findings regarding changes in mGluR5 expression extend to human cocaine users (CU) has not been investigated to date. The positron emission tomography (PET) radioligand 11 C-ABP688 (3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-enone-O-carbon-11-methyl-oxime) 33, 34 has made it possible to quantify mGluR5 availability in humans. A recent PET study applying this ligand has demonstrated that smokers exhibit globally lower cerebral mGluR5 density. 35 However, it is not clear if mGluR5 alterations are specific for nicotine addiction or a common phenomenon in drug addiction. Therefore, the aim of the present study was to quantify mGluR5 availability in addictionrelated brain regions employing 11 C-ABP688 PET in CU and drugnaïve controls. Additionally, we investigated the potential impact of smoking on mGluR5 availability in CU. We expected that both cocaine and tobacco use decrease mGluR5 availability in corticolimbic brain regions.
MATERIALS AND METHODS Participants
The study sample consisted of 18 male drug-naïve healthy control subjects (HC) and 18 male CU who also took part in the longitudinal Zurich Cocaine Cognition Study (ZuCo 2 St). [36] [37] [38] Participants were recruited via advertisements in local newspapers, different drug prevention and treatment centers, psychiatric hospitals, internet platforms, and word-ofmouth communication (for details see Preller et al.
37
). Inclusion criteria for CU were (1) diagnosis of cocaine abuse or dependence according to DSM-IV, 39 (2) age between 20 and 50 years, (3) proficiency in German language, (4) no polytoxic drug use pattern and no use of prescription drugs affecting the CNS, (5) no current or previous Axis I DSM-IV psychiatric disorder (other than cocaine abuse/dependence, alcohol abuse in CU, and a former depression), (6) no neurological disorder or head injury, (7) no family history of a severe DSM-IV psychiatric disorder such as schizophrenia, bipolar disorder or obsessive-compulsive disorder, and (8) no metal parts in the body. The same inclusion criteria applied to HC except for (1) . Additionally, HC were excluded if they regularly engaged in illegal drug use (415 occasions) with exception of cannabis use. Participants were instructed to abstain from illegal drugs for X3 days and X24 h from alcohol. Urine samples were collected to control for recent drug use. To objectively characterize drug use over the past 6 months, hair samples (6 cm) were collected and analyzed with liquid chromatographymass spectrometry (see Supplementary Material). Participants received financial compensation. This study was approved by the Ethics Committee of the Canton Zurich and the Swiss Federal Office of Public Health. All participants provided written informed-consent before inclusion.
Clinical interviews and questionnaires
The Structured Clinical Interview for DSM-IV Disorders was carried out by a trained psychologist. 39 Drug use was assessed by means of the Interview for Psychotropic Drug Consumption, which has been described in detail elsewhere. 40 The Beck Depression Inventory was used to assess symptoms of depression. 41 The Symptom Checklist-90-R served as a screening measure for general psychiatric symptoms. 42 The brief version of the Cocaine Craving Questionnaire was used to assess current cocaine craving. 43, 44 The Fagerströ m Test for Nicotine Dependence was used to determine severity of nicotine dependence. 45 
Image acquisition and data analyses
Magnetic resonance image acquisition. T1-weighted magnetic resonance imaging was acquired for each participant on a Philips Achieva 3T wholebody scanner equipped with a transmit/receive head coil (Philips Healthcare, Best, The Netherlands) to rule out structural abnormalities and for the preprocessing of PET images.
PET acquisition. The synthesis of 11 C-ABP688 has been described in detail elsewhere. 33, 34 PET image acquisition was conducted in 3-D mode in the whole-body scanner DSTX PET/computed tomography scanner (B Braun Medical, Sempach, Switzerland) at the Division of Nuclear Medicine of the University Hospital Zurich. Before the PET acquisition, a catheter was placed in the left antecubital vein for tracer injection and a low-dose CT was conducted for attenuation correction. In order to avoid inconvenient arterial blood sampling, we relied on a previously evaluated equilibrium paradigm 46, 47 based on the premise that a steady state between tracer concentration in tissue and blood can be obtained. 48 , 49 11 C-ABP688 was administered according to a bolus-infusion protocol, 46, 49 To verify that steady state of receptor binding was reached after 45 min (frames 17-19), time-activity curves were generated for high (ACC, putamen), medium (thalamus) and low receptor density regions (cerebellum) in both hemispheres for all participants. Steady state of 11 C-ABP688 uptake 45 min after tracer injection was reached in all participants, save one control subject, who was therefore excluded from the subsequent statistical analyses. Normalized values of distribution
C-ABP688 uptake constituted the quantitative PET outcome measure and were derived by dividing the average radioactivity concentration between 45 and 55 min (frames 17-19) of each VOI (C T [VOI] ) with the commensurate cerebellar radioactivity concentration
51 mGluR5 has been successfully quantified with this approach in previous studies 46, 52, 53 and a preclinical study showed that the cerebellum is relatively devoid of mGluR5 and thus suitable as a reference region. 54 
Statistical Analysis
Statistical analyses were performed with the IBM SPSS Statistics 19.0 software (SPSS Inc.). Independent t-tests and frequency analyses (Pearson's w 2 -test) were conducted to compare groups among demographic and clinical questionnaire data. PET data were analyzed with a mixed-effect analysis of variance including the between-subject factors group (HC, CU) and smoking status (non-smokers, smokers), the within-subject factors brain region (12 VOIs) and hemisphere (left, right), and their interactions. Two-tailed independent t-tests were conducted to identify differences of 11 C-ABP688 uptake in the selected VOIs between groups. To account for multiple testing, the Bonferroni-correction was applied, resulting in a significance level of Po0.0042 (P ¼ 0.05/12). Potential associations of drug use parameters and mGluR5 availability were examined with correlation analyses (Pearson's product-moment). Effect sizes (Cohen's d) were calculated with G*Power 3.1. 55 As the assumption of parametric distribution was not met by certain variables, the drug use parameters weekly cigarette use, weekly alcohol, cannabis, and cocaine consumption (g), last alcohol, cigarette, cannabis, and cocaine use (h), cumulative cannabis and cocaine dose (g), and concentrations of cocaine and its metabolites in the hair samples (pg mg À 1 ) were log-transformed (log10) and the constant 1 was added because the data contained 0 values.
RESULTS
Demographic information and drug use patterns HC and CU were well-matched for age, smoking status, symptoms of depression and years of education, and did not differ with regard to the SCL-90 and Fagerströ m Test for Nicotine Dependence scores (Table 1) . Nine (50%) of the CU met the DSM-IV criteria for current cocaine dependence, whereas the remaining 9 CU met whereas the remaining 9 CU met the criteria for cocaine abuse. Except for one CU who reported smoking crack cocaine, all other CU indicated to use cocaine nasally. None of the participants met the criteria for alcohol dependence. Drug use patterns are mGluR5 density in smokers and cocaine users LM Hulka et al shown in Table 2 . CU and HC did not differ in cigarette use. However, CU reported higher weekly alcohol consumption (t(33) ¼ À 2.84, Po0.05) and higher cumulative doses of cannabis (t(33) ¼ À 2.17, Po0.05). CU had a mean weekly cocaine consumption of 1.5 g, while they reported very little co-use of amphetamine and MDMA. Hair toxicology analyses capturing the past 6 months confirmed that cocaine was the primary drug of choice in all CU. Methamphetamine and opiates were not detected, while mean amphetamine values were very low. It is noteworthy that 44% of the CU tested positive for cocaine in the urine toxicology. Therefore, additional analyses were carried out to investigate post-acute effects of cocaine use.
11 C-ABP688 uptake in controls, CU, and smokers
In accordance with previous reports, 34,53,56 regional 11 C-ABP688 uptake was highest in mGluR5-rich regions such as the ACC, caudate, insula, and putamen, while 11 C-ABP688 binding was lower in the thalamus (Figures 1a and b and 2a and b) .
11 C-ABP688 uptake did not differ between HC and CU ( Figures  1a and 2a ), yet differed substantially between non-smokers (n ¼ 11) and smokers (n ¼ 24) (Figures 1b and 2b) . Table S1 ) and the effect was present in CU and controls (Supplementary Figure S1) . Notably, when only non-smoking CU (n ¼ 5) were compared with non-smoking HC (n ¼ 6), there was a weak trend for lower mGluR5 availability in the caudate nucleus of CU (t(9) ¼ 1.87, P ¼ 0.095, d ¼ 1.01). Moreover, heavy smokers showed slightly lower mGluR5 availability than light smokers (Supplementary Figure S2) . 11 C-ABP688 uptake in all VOIs correlated significantly with age in CU (n ¼ 18, r ¼ 0.51-0.58, Po0.05) and smokers ((n ¼ 24, 13 CU and 11 HC), r ¼ 0.41-0.52, Po0.05; except for the hippocampus and amygdala P ¼ 0.12), but not in HC in general (n ¼ 17, P40.88). Moreover, 11 C-ABP688 uptake was significantly negatively associated with age in non-smokers in the putamen ((n ¼ 11, CU ¼ 5, HC ¼ 6), r ¼ À 0.65, Po0.05).
Drug use parameters and 11 C-ABP688 uptake In order to reduce the probability of a-error accumulation, three combined brain regions were derived by averaging the V norm values of the OFC, ACC, MPFC, DLPFC, VLPFC (frontal cortex), the V norm values of the caudate and the putamen (striatum), and the V norm values of the amygdala, parahippocampal gyrus, and the hippocampus (medial temporal lobe; MTL). The insula and the thalamus were not combined with other brain 
Abbreviations: MDA, 3,4-methylenedioxyamphetamine; MDEA, methylenedioxyethylamphetamine; MDMA, 3,4-methylenedioxy-N-methylamphetamine; neg., negative; pos., positive.
a Consumption per day/week captures the last 6 months, duration of use and cumulative dose are averaged within the total group. Last consumption is averaged only for subjects who used the drug in the last 6 months. In this case, sample size is shown. The hair analysis was performed on two hair samples (each 3 cm in length) per participant capturing drug use over the last 6 months. Concentrations were averaged over the two samples. If the hair sample was not long enough, only one sample was analyzed (3 cm, 3 months).
mGluR5 density in smokers and cocaine users LM Hulka et al regions. To prevent inflating potential associations, for correlation analyses regarding drug use only users of the specific drug were included. There were no significant associations of alcohol, cannabis, and cocaine use (times or g per week, last use, duration in years, cumulative dose in g) with mGluR5 availability, except for age of cocaine onset (r Striatum VOI ¼ 0. 47 Figure 3 ). Moreover, age of onset of smoking correlated positively with mGluR5 availability in the frontal VOI (r ¼ 0.41, Po0.05) and thalamus (r ¼ 0.45, Po0.05), but this result also did not survive correction for age (P40.31).
Eight out of 18 CU tested positive for cocaine in the urine toxicology. Therefore, mGluR5 availability was compared among controls (n ¼ 17), CU who tested negative (n ¼ 10), and CU who tested positive for cocaine (n ¼ 8). There was no significant group difference for all VOIs indicating that recent cocaine use did not alter mGluR5 density in CU. The same analysis was repeated with cannabis urine toxicology status, but recent cannabis use did also not affect our results. Cocaine craving scores did not correlate with mGluR5 availability in CU.
DISCUSSION
This is the first study to investigate mGluR5 availability in human CU vs psychostimulant-naïve control subjects. The CU sample was unique in terms of very little co-use of other illicit drugs verified by hair toxicology, and sparse psychiatric co-morbidities. The key findings are that cocaine use was not significantly associated with altered mGluR5 density. However, in a small subsample of nonsmokers, CU exhibited a trend for lower mGluR5 availability in the caudate nucleus in comparison with HC. In line with a recent study, 35 smokers exhibited globally lower mGluR5 density of on average 20% compared with non-smokers. The time interval since showed significantly lower mGluR5 density in all regions of interest compared with non-smokers (n ¼ 11) irrespective of cocaine use. The percent difference of mGluR5 density in non-smokers and smokers ranged from 14 to 21 percent. *Indicates significant differences (Po0.0001). Ant. cingulate cortex, anterior cingulate cortex; ventrolat. prefrontal cortex, ventrolateral prefrontal cortex; dorsolat. prefrontal cortex, dorsolateral prefrontal cortex. mGluR5 density in smokers and cocaine users LM Hulka et al smoking the last cigarette correlated with mGluR5 density in all regions of interest, reflecting that the lower mGluR5 availability was particularly pronounced in individuals who had smoked very recently. Interestingly, although older age was associated with higher mGluR5 availability in CU and smokers, an opposing trend was observed in non-smokers, whereas no significant correlations between age and mGluR5 availability were found in controls.
With the present study, we replicated the recent finding that smoking is associated with markedly lower 11 C-ABP688 uptake 35 either representing altered affinity of the binding site or lower mGluR5 density. As G-protein coupled receptors have the ability to undergo endocytosis in response to changes in extracellular levels of receptor agonists, 57 the notion that the 20% lower mGluR5 availability in smokers constitutes a mechanism to attenuate excessive signaling by downregulation or internalization seems probable. [58] [59] [60] Indeed, the fact that longer smoking abstinence was associated with increased mGluR5 availability may reflect the dynamic nature of mGluR5 trafficking and supports the assumption of nicotine-induced changes. Alternatively, reduced mGluR5 availability may constitute a preexisting condition that increases the risk for nicotine dependence. The average mGluR5 reduction observed in our study was remarkably in accordance with recent independent data. 35 Although mGluR5 availability was slightly lower in the caudate nucleus compared with other brain regions in smokers, we did not find a strong region-specific decrease as was previously revealed for the medial OFC in smokers. 35 Moreover, cigarettes smoked per week and severity of nicotine dependence in our study did also not correlate with mGluR5 availability. Furthermore, we failed to find a significant association between smoking duration and mGluR5 availability. However, when Akkus et al. 35 took age into account the association was not significant either. A notable difference emerged with regard to smoking abstinence, where we found that briefer smoking abstinence was associated with lower mGluR5 availability. This divergent finding is likely explained by the fact that smokers exhibited a larger variance of abstinence periods in our study increasing the likelihood to detect significant correlations.
mGluR5s have directly been linked to drug-seeking behavior and extinction learning in animals withdrawn after cocaine selfadministration (for review see Bellone and Mameli, 19 Duncan and Lawrence, 20 and Kenny and Markou 61 ). Preclinical studies have shown that chronic self-administration of cocaine disrupts synaptic communication between the PFC and the striatum and results in decreased basal levels of non-synaptic, extracellular glutamate in the NAcc. 11, [62] [63] [64] [65] Reduced extracellular glutamate tone in the NAcc core has in turn been associated with downregulation of mGluR5 expression and function in rats, [12] [13] [14] [15] [16] [17] resulting in disrupted synaptic plasticity, which is assumed to contribute to the persisting nature of addiction. 9 It has been proposed, that the observed downregulation of mGluR5s and Homer1b/c, post-synaptic scaffolding proteins influencing mGluR5 trafficking and signal transduction after chronic cocaine administration may constitute a compensatory mechanism, as mGluR5 antagonists attenuate drug-seeking behaviors. 9 Interestingly, extinction training was also associated with a marked decrease in mGluR5 expression and elevated levels of Homer proteins, possibly providing further support for compensatory adaptation, which may inhibit relapse. 66 Moreover, it has been suggested that genetic variations in mGluR5s, when resulting in decreased mGluR5-mediated neurotransmission, may render such individuals less sensitive to the reinforcing effects of cocaine and nicotine, as well as aversive states during withdrawal as the chromosomal region 11q14, on which the mGluR5 gene (GRM5) is located has been associated with habitual smoking behavior. 67, 68 Even though findings from preclinical and human studies are not directly comparable, it is noteworthy that preclinical cocaine studies found specifically reduced mGluR5 expression in the NAcc core and failed to find alterations in mGluR5 expression in the PFC and the amygdala, which is consistent with our study. 13, 16, 17, 69 As we only found a trend for lower mGluR5 availability in the caudate in a small subsample of non-smoking CU compared with nonsmoking HC, it is possible that the small statistical power and the strong global effect associated with tobacco smoking in the overall study sample may have masked cocaine-related effects on mGluR5 availability. Moreover, not all CU met criteria for dependence and 44% tested positive for cocaine in the urine toxicology.
The question arises why cocaine use did not seem to alter mGluR5 availability, while tobacco smoking did so in a very pronounced and global manner. In contrast to cocaine, nicotine has the ability to directly increase glutamate release by binding to nicotinic acetylcholine receptors that are located on presynaptic terminals of glutamatergic neurons in the PFC, ventral tegmental area, NAcc, amygdala and the hippocampus. 70 This might explain the strong smoking effect on mGluR5 availability observed in the present study. In contrast, cocaine binds to monoamine transporters (dopamine, serotonin and noradrenaline), which are mainly localized in the basal ganglia but only show low density in most regions of the neocortex. 71 Acute cocaine intake may therefore exert its function on glutamatergic transmission in a more indirect and less global manner compared with nicotine. Finally, in agreement with our findings, preclinical studies demonstrated specific cocaine-induced alterations of mGluR5 expression primarily in the NAcc core rather than globally. [12] [13] [14] [15] [16] [17] Some limitations of the present report merit comment. (i) Owing to limited spatial resolution of PET imaging, we cannot fully exclude the possibility that CU may have exhibited subtle differences especially in the NAcc core region in comparison with (ii) The present study cannot conclusively answer if the reduced mGluR5 availability in smokers represents a pre-existent condition or is indeed acquired. (iii) A PET study using the radioligand 18 F-FPEB reported that the human cerebellum is not entirely devoid of mGluR5s. 72 However, a more recent study with 18 F-FPEB demonstrated that using the cerebellum as a reference region may be feasible to quantify mGluR5 density. 73 Additional support for negligible mGluR5 binding in the cerebellum comes from prior in vitro and in vivo studies with the radioligand 11 C-ABP688. 54, 74 (iv) The strong influence of recent tobacco use may have masked less pronounced cocaine-related effects on mGluR5 expression.
In conclusion, tobacco smoking was associated with a globally lower mGluR5 density of 20%, while only a weak trend was found for decreased mGluR5 availability specifically in the caudate nucleus in a small non-smoking CU subsample. In particular, briefer smoking abstinence duration was associated with lower mGluR5 density pointing to the possibility of nicotine-induced downregulation or internalization of mGluR5s. These findings provide evidence that mGluR5s are involved in nicotine addiction and may have important implications with regard to the development of potential pharmacotherapies aimed at facilitating smoking cessation. If compounds targeting mGluR5s are effective in preventing relapses in human CU akin to preclinical findings remains to be determined. As the systematic investigation of neuroadaptations in humans is much more complicated because of constraints in experimental manipulation that is only possible in preclinical research, it would be informative to apply multimodal imaging in human CU. For instance, glutamate levels in the NAcc and PFC measured by means of magnetic resonance spectroscopy and how these levels are related to mGluR5 availability, PFC metabolism and perfusion in different stages of addiction (for example, acute drug intake/relapse, craving, withdrawal) could be insightful to unmask neuroadaptations in drug-addicted humans. 
